ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 872,99
0,17%
DAX
18 726,76
-0,21%
Brent Oil
82,175
-0,33%
Bitcoin
69 921,90
-0,30%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. FibroGen Inc (FGEN)

  7. FibroGen Inc (FGEN) Actualités

FGEN

FibroGen (FGEN)

FibroGen Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:FGEN
DateHeureSourceTitreSymboleSociété
07/05/202417h55AllPennyStocks.comTraders Rush To Buy Biotech Following Q1 Earnings BeatNASDAQ:FGENFibroGen Inc
07/05/202413h00GlobeNewswire Inc.FibroGen to Participate in Upcoming Investor ConferencesNASDAQ:FGENFibroGen Inc
06/05/202422h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FGENFibroGen Inc
06/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FGENFibroGen Inc
06/05/202422h02GlobeNewswire Inc.FibroGen Reports First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
29/04/202413h00GlobeNewswire Inc.FibroGen to Report First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
24/04/202422h02GlobeNewswire Inc.FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology ANASDAQ:FGENFibroGen Inc
02/04/202423h46GlobeNewswire Inc.FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:FGENFibroGen Inc
26/03/202412h00GlobeNewswire Inc.FibroGen to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:FGENFibroGen Inc
11/03/202412h00GlobeNewswire Inc.FibroGen Appoints Deyaa Adib, M.D. as Chief Medical OfficerNASDAQ:FGENFibroGen Inc
09/03/202401h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
26/02/202422h06GlobeNewswire Inc.FibroGen Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
26/02/202422h05GlobeNewswire Inc.FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South KoreaNASDAQ:FGENFibroGen Inc
20/02/202413h00GlobeNewswire Inc.FibroGen to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
14/02/202421h37Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FGENFibroGen Inc
05/02/202413h00GlobeNewswire Inc.FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024NASDAQ:FGENFibroGen Inc
25/01/202413h00GlobeNewswire Inc.FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic CancerNASDAQ:FGENFibroGen Inc
09/12/202323h02GlobeNewswire Inc.FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual MeetingNASDAQ:FGENFibroGen Inc
06/11/202322h01GlobeNewswire Inc.FibroGen Reports Third Quarter 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
23/10/202313h00GlobeNewswire Inc.FibroGen to Report Third Quarter 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
01/09/202323h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FGENFibroGen Inc
29/08/202322h15GlobeNewswire Inc.FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular DystrophyNASDAQ:FGENFibroGen Inc
07/08/202322h22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FGENFibroGen Inc
07/08/202322h01GlobeNewswire Inc.FibroGen Reports Second Quarter 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
25/07/202313h00GlobeNewswire Inc.FibroGen Announces Leadership TransitionNASDAQ:FGENFibroGen Inc
24/07/202313h00GlobeNewswire Inc.FibroGen to Report Second Quarter 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
26/06/202322h28Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FGENFibroGen Inc
26/06/202315h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FGENFibroGen Inc
26/06/202313h04GlobeNewswire Inc.FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary FibrosisNASDAQ:FGENFibroGen Inc
08/06/202323h52Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:FGENFibroGen Inc
 Showing the most relevant articles for your search:NASDAQ:FGEN

Dernières Valeurs Consultées

NASDAQ
AAPL
Apple
USI
USTECH100
US Tech 100
EU
ML
Michelin
EU
ACA
Credit Agricole
EU
MC
Lvmh Moet Hennessy Louis...
EU
BNP
BNP Paribas
EU
CS
Axa
EU
RI
Pernod Ricard
NYSE
DIS
Walt Disney
EU
GLE
Societe Generale
EU
CAP
Capgemini
EU
AI
Air Liquide
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés